Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Malcolm Spicer

Senior Editor, Consumer Health

Washington, DC
Malcolm Spicer is lead analyst for Pharma intelligence | informa's coverage of the consumer health care products industries. He provides comprehensive and insightful reporting on manufacturing, marketing, regulation, legislation, financial and research news about the nonprescription drug and nutritional product industries. He has worked in this post for 10 years and previously reported for other publications on regulation of the health care industry, on the telecommunications and internet technologies and on the US energy market.
Advertisement
Set Alert for Articles By Malcolm Spicer

Latest From Malcolm Spicer

Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector

Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue  to be subject to Chinese import tariffs.

 

Consumer China

Clash Of The Power Toothbrush Titans: P&G Challenges Philips' Sonicare Claims, Both Firms Appeal NAD Decision

Following its review of the two firms' latest clash over power brush claims, Council of Better Business Bureau's investigative division says Philips and P&G are appealing its recommendations within the industry self-regulation process.The recommendations were from a review conducted on the second challenge P&G made in a year on Philips' ads comparing the two firms' product.

Commercial Consumer

Higher Consumer Health Price Tags Ahead As Chinese Import Tariff Increases

Additional tariffs on Chinese imports of ingredients needed for dietary supplements in addition to active ingredients and excipients used in OTC drugs will increase manufacturers' costs even if they arrange to receive ingredients from firms in the US of other countries. The American Herbal Products Association told USTR that firms impacted by the additional tariff "will be faced with the need to either increase prices and thus risk sales losses, absorb additional costs by reducing profit margins, or discontinue products; each of these options risks economic harm to these companies and job losses to their employees."

Dietary Supplements Commercial

Freshkote Buy Narrows Eyevance's Focus

Agreement with Focus Laboratories includes all Freshkote formulations in multi-dose bottles and single-unit vials to market and commercialize the line worldwide.

Deals Ophthalmic

GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business

Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.

Consumer M & A

FDA OTC Switch Guidance Omits Some Turns As Approval Roadmap, CHPA Says

In its comment on draft guidance, OTC industry trade group urges US FDA to issue final guidance on "Innovative Approaches For Nonprescription Drug Products" in addition to a rule the agency has indicated would soon follow.  CHPA expects that identifying information away not within a Drug Facts label that will be considered in an FDA evaluation would be determined on a case-by-case basis, with a switch NDA sponsor and the agency agreeing to terms of approval during a proposal development and review.

Prescription To Otc Switch Drug Approval Standards
See All
Advertisement
UsernamePublicRestriction

Register